BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...

Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs. In its second-quarter ...

After its last attempt at a merger failed in 2023, Redx Pharma seems to have found a willing partner in Skye Bioscience, which experienced a couple of trial failures in recent years. The public ...

Under the terms of its 2022 deal with Taiho, Cullinan is in line to receive $30 million when zipalertinib is approved for second-line use and $100 million when it secures a first-line nod from the FDA ...

Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture. Hoffman co-founded Khartis Therapeutics in 2024 with other former leaders of ...

PTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sangamo ...

As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million. Takeda and Protagonist ...

Boulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates. | Boulevard Bio has strolled out of stealth with $65 million in ...

A new analysis from the Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical monitoring agent can deliver 82 times the return on investment (ROI) in oncology trials. | A new ...

Sixty per cent of aTyr Pharma’s workforce are heading for the exits as the biotech conserves resources for a second shot at phase 3 success in a type of lung disease. Last year, aTyr revealed that its ...

“The question early on was what mechanisms we wanted,” Madrigal CEO Bill Sibold told Fierce in an interview at the company’s ...